Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer

Novo Nordisk (NYSE: NVO) banal has fallen 28% this twelvemonth arsenic investors fearfulness that it's falling down successful the competitory GLP-1 market. The institution inactive has immoderate unthinkable blockbuster drugs successful its portfolio, including Ozempic and Wegovy, but it expects its gross to diminution this twelvemonth arsenic a effect of rising competition.

Recently, however, the institution received immoderate large quality from regulators, with the support of a higher-dose mentation of Wegovy, which it volition simply telephone Wegovy HD. While it whitethorn look similar a tiny occurrence for the healthcare company, here's wherefore it tin beryllium a important crippled changer and pb to overmuch amended maturation for the business, successful some the abbreviated word and the agelong term.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Earlier this month, the Food and Drug Administration approved Wegovy HD, which is simply a higher-dose (7.2 mg) mentation of Wegovy. Up until now, the highest dose disposable was 2.4 mg.

What's promising is that the value nonaccomplishment achieved with Wegovy HD is much effectual and tin assistance the institution amended vie against its rival, Eli Lilly. Using Wegovy HD, radical mislaid an mean of 20.7% of their assemblage value successful a objective trial. While that's inactive little than the 22.5% that patients suffer with Eli Lilly's Zepbound, the quality is acold smaller than the regular dose of Wegovy, which averages astir 15%.

By bridging the gap, the determination to usage 1 cause implicit different whitethorn nary longer beryllium astir sheer value nonaccomplishment imaginable but alternatively astir which is much tolerable, and that tin alteration importantly from 1 idiosyncratic to the next. For Novo Nordisk, this puts it successful a much competitory presumption and, thus, tin assistance it triumph backmost marketplace stock and make amended numbers. Earlier this year, it unveiled a troubling forecast, which called for gross to diminution by arsenic overmuch arsenic 13% successful 2026.

Despite the bully quality for the institution with the support of Wegovy HD, determination remains plentifulness of bearishness astir Novo Nordisk's stock. It's trading astir its 52-week low, and its price-to-earnings ratio is conscionable implicit 10, which suggests investors are discounting it heavy owed to the uncertainty and hazard ahead. But with Wegovy HD, the institution looks to beryllium successful acold amended signifier than it was anterior to the drug's approval.

For semipermanent investors, present tin beryllium an optimal clip to adhd the banal to your portfolio. There's immoderate coagulated worth with Novo Nordisk stock. Its valuation is low, and it besides pays a precocious dividend that yields conscionable implicit 5%. This is simply a reasonably underrated and undervalued banal close now, which could person tremendous upside down the road.